SRX 0.00% $33.55 sirtex medical limited

more good srx news

  1. 2,773 Posts.


    Sirtex Announces New Medical Director for U.S. Operations


    WILMINGTON, Mass.-Sirtex Medical July 14
    About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres

    Selective Internal Radiation Therapy (SIRT) is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumors. In a minimally-invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

    Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity, and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.

    SIRT using SIR-Spheres microspheres is approved for use in Australia, New Zealand, the United States of America (FDA approval), European Union (CE Mark), Hong Kong, Malaysia, Singapore, Thailand, Israel, and India. SIRT is available in 140 treatment centers around the world, and more than 6500 patients have been treated to date.

    Approximately 90 physicians in the United States use Sirtex's SIR-Spheres microspheres in more than 86 medical centers. For more information, visit www.sirtex.com.

    (R) SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd

    Contact

    For Sirtex
    Andrea Moody, 919-457-0743
    [email protected]




    Printer Friendly Version Forward to a Friend


    Get Instant Access to our News Archive
    For more than 20 years, executives like you have relied on Engel Publishing Partners for the business, marketing, and clinical research information needed to make informed business decisions. InfoPass gives you access to an array of integrated information services – information that is critical to your success and the success of your organization.
    Login or activate your InfoPass Account now!








    search by news archive Med Ad News R&D Directions entire archive


    Subscriber registration
    Purchase a subscription
    Forget your password
    Need help?
    Your account details
    Order back issues
    Renew subscription
    Free trial issues





    about us | advertise on pharmalive | contact us | home
    terms of use | privacy | copyright | site map © 2007 Engel Publishing Partners

 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.